Alpha Teknova is a cash-burning, below-floor-quality small cap whose shares are already above the engine's target, leaving little upside despite narrowing losses and revenue growth.
Thesis pillars
- Quality Below Floor→Stable
- Target Already Exceeded↓Deteriorating
- Narrowing Quarterly Losses↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 11, 2026, based on the 10-K filed Mar 2, 2026
Alpha Teknova, Inc. (TKNO) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $7.86: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 15%; Elevated put/call ratio: 11.00; Below-average business quality.
Alpha Teknova makes reagents, media and custom-formulated products for life-science research, diagnostics and cell and gene therapy customers, almost all in the U.S. Lab Essentials contributed 76.6% of 2025 revenue and Clinical Solutions 18.9%. Customers buying more than $10,000... Read more
Sell if holding. Engine safety override at $7.86: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 15%; Elevated put/call ratio: 11.00; Below-average business quality. Chart setup: RSI 46 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: aggressive.
Recent developments
updated 2026-10-29Recent Developments — Alpha Teknova, Inc.
Latest news
- NEWS Alpha Teknova, Inc. to Report Third Quarter 2026 Financial Results on November 4, 2026 — fiscal.ai Oct 22, 2026
- NEWS Tesla, Lam Research, Rollins And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session — benzinga Oct 22, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Wednesday's Intraday Session — benzinga Oct 21, 2026 neutral
- NEWS Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings — benzinga Oct 21, 2026
- NEWS Dow Gains Over 100 Points; AT&T Earnings Top Views — benzinga Oct 21, 2026
Generated 2026-10-29T11:08:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductLab Essentials business77%10-K Item 1: 'our Lab Essentials business contributed 76.6% of our total revenue'
- HIGHGeographiccustomers in the U.S.94%10-K Item 1: 'In 2025, revenue from sales to customers in the U.S. represented 94.4% of our total revenue.'
- MEDIUMSuppliertwo suppliers of inventory purchases10-K Item 1A: 'individually each made up 10% or more of our total inventory purchases, and these suppliers comprised 56% of our total inventory purchases in the aggregate.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Unprofitable operations — net margin -38.4%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.86: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 15%; Elevated put/call ratio: 11.00; Below-average business quality. Chart setup: RSI 46 mid-range, Bollinger mid-band. Prior stop was $7.31. Score 5.4/10, moderate confidence.
Analyst target: $8.41 (+7.0% upside). Prior stop was $7.31. Stop-loss: $7.31.
Concentration risk — Product: Lab Essentials business (76.6%); Concentration risk — Geographic: customers in the U.S. (94.4%); Quality below floor (2.6 < 4.0).
Alpha Teknova, Inc. trades at a P/E of N/A (forward -41.4). TrendMatrix value score: 4.7/10. Verdict: Sell.
14 analysts cover TKNO with a consensus score of 4.3/5. Average price target: $10.
What does Alpha Teknova, Inc. do?Alpha Teknova makes reagents, media and custom-formulated products for life-science research, diagnostics and cell and...
Alpha Teknova makes reagents, media and custom-formulated products for life-science research, diagnostics and cell and gene therapy customers, almost all in the U.S. Lab Essentials contributed 76.6% of 2025 revenue and Clinical Solutions 18.9%. Customers buying more than $10,000 annually were about 85% of 2025 revenue.